H.C. Wainwright raised the firm’s price target on Blueprint Medicines to $125 from $85 and keeps a Buy rating on the shares. The analyst says the key pillar of the firm’s thesis for Blueprint has always been that indolent systemic mastocytosis is a real and accessible market with blockbuster potential. The firm increased revenue assumptions and slope of launch penetration for Ayvakit following the company’s Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BPMC:
- Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
- Blueprint Medicines price target raised to $70 from $58 at Barclays
- BPMC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Blueprint Medicines price target raised to $90 from $85 at Oppenheimer
- Blueprint Medicines price target raised to $78 from $58 at Piper Sandler
